Patrick Wood
Stock Analyst at Morgan Stanley
(2.18)
# 2,792
Out of 5,172 analysts
121
Total ratings
41.67%
Success rate
-2.11%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $23 → $25 | $24.82 | +0.73% | 7 | Mar 2, 2026 | |
| MDLN Medline | Maintains: Overweight | $48 → $52 | $42.73 | +21.69% | 2 | Mar 2, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $80 → $85 | $69.65 | +22.04% | 9 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $130 → $118 | $69.48 | +69.83% | 8 | Feb 5, 2026 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $76 → $83 | $69.96 | +18.64% | 7 | Dec 8, 2025 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $123 → $135 | $113.90 | +18.53% | 3 | Dec 2, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $9 → $10 | $6.44 | +55.28% | 3 | Dec 2, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $56 → $51 | $25.79 | +97.75% | 4 | Dec 2, 2025 | |
| DXCM DexCom | Upgrades: Overweight | $63 → $75 | $66.95 | +12.02% | 10 | Dec 2, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $197 → $210 | $154.13 | +36.25% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $19 → $15 | $16.15 | -7.12% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $14 → $21 | $15.72 | +33.59% | 9 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $80 | $73.65 | +8.62% | 5 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $276 → $295 | $220.03 | +34.07% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $81 | $82.50 | -1.82% | 9 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $65.78 | +56.58% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $100.99 | -28.71% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $105.41 | +64.12% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $227.10 | +39.59% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $17.52 | +111.19% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $149.31 | - | 5 | Dec 11, 2017 |
Tandem Diabetes Care
Mar 2, 2026
Maintains: Equal-Weight
Price Target: $23 → $25
Current: $24.82
Upside: +0.73%
Medline
Mar 2, 2026
Maintains: Overweight
Price Target: $48 → $52
Current: $42.73
Upside: +21.69%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Equal-Weight
Price Target: $80 → $85
Current: $69.65
Upside: +22.04%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $130 → $118
Current: $69.48
Upside: +69.83%
The Cooper Companies
Dec 8, 2025
Maintains: Equal-Weight
Price Target: $76 → $83
Current: $69.96
Upside: +18.64%
TransMedics Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $123 → $135
Current: $113.90
Upside: +18.53%
RxSight
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $6.44
Upside: +55.28%
PROCEPT BioRobotics
Dec 2, 2025
Maintains: Overweight
Price Target: $56 → $51
Current: $25.79
Upside: +97.75%
DexCom
Dec 2, 2025
Upgrades: Overweight
Price Target: $63 → $75
Current: $66.95
Upside: +12.02%
Becton, Dickinson and Company
Dec 2, 2025
Maintains: Overweight
Price Target: $197 → $210
Current: $154.13
Upside: +36.25%
Dec 2, 2025
Maintains: Underweight
Price Target: $19 → $15
Current: $16.15
Upside: -7.12%
Dec 2, 2025
Upgrades: Overweight
Price Target: $14 → $21
Current: $15.72
Upside: +33.59%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $73.65
Upside: +8.62%
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $220.03
Upside: +34.07%
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $82.50
Upside: -1.82%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $65.78
Upside: +56.58%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $100.99
Upside: -28.71%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $105.41
Upside: +64.12%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $227.10
Upside: +39.59%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $17.52
Upside: +111.19%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $149.31
Upside: -